Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ImmuneRegen BioSciences has said that Viprovex has demonstrated the potential for treating potentially resurgent spanish flu, avian flu and other infectious diseases based upon studies in animal models.
Subscribe to our email newsletter
Viprovex showed protection from infection by Bacillis anthracis and influenza A viruses.
Studies looking at potential mechanisms have examined cellular components of the host immune system and have found that in both animals and in cultured cells, Viprovex causes differential activation of components of the innate immune system. This supports the whole animal findings and suggests that Viprovex may be capable of thwarting the immune system over-stimulation which might underlie the severe lethality of Spanish flu as well as bird flu.
In studies, cotton rats treated with Viprovex displayed diminished intrapulmonary and intrapharyngeal viral titers as well as enhanced well-being.
Current studies are planned to confirm findings in animal models for H5N1 and Spanish flu, as well as expand efficacy observations against anthrax to viral diseases such as hepatitis C and dengue fever.
Based on this work, the company believes that focusing on infectious disease applications will continue to be its scientific and business strategy.